For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Survodutide (BI 456906) is an investigational once-weekly subcutaneous peptide that acts as a dual agonist at both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). In Phase 2 trials, it produced up to 18.7% weight loss at 46 weeks (completers; 4.8 mg dose) versus 2.3% placebo (Le Roux et al. 2024, Lancet Diabetes Endocrinology; n=386). In a separate Phase 2 MASH trial, 62% of participants receiving 4.8 mg achieved histologic MASH resolution without worsening fibrosis versus 14% placebo (Sanyal et al. 2024, NEJM; n=293; 48 weeks). The FDA granted Breakthrough Therapy designation for MASH in September 2024. Phase 3 SYNCHRONIZE trials (obesity) and LIVERAGE trials (MASH) are fully enrolled; results expected H1 2026. The primary safety concern is GI tolerability: 25% of survodutide recipients discontinued due to AEs (mostly GI) versus 4% placebo.
Survodutide is not yet approved for any indication. It is an investigational pharmaceutical drug in Phase 3 clinical development, not a research chemical or supplement. Readers should not attempt to obtain or use survodutide outside of a formal clinical trial. There is no compounding authorization and no off-label prescribing pathway since no on-label use exists.
The Phase 2 results are genuinely impressive, particularly the MASH data published in the NEJM. However, Phase 2 efficacy frequently does not fully replicate in Phase 3 due to larger, more heterogeneous populations, longer follow-up, and stricter endpoints. The SYNCHRONIZE Phase 3 trials will provide the definitive efficacy picture; Phase 3 results are expected in H1 2026.
The 25% treatment discontinuation rate due to adverse events in the Phase 2 obesity trial (versus 4% placebo) is the most clinically significant safety signal. Most discontinuations were GI-related and occurred during the dose-escalation phase, suggesting this can be mitigated by slower escalation. The Phase 3 design implements a more gradual escalation schedule. Despite the high AE rate, serious adverse events were less frequent in the survodutide group (4%) than placebo (7%), reflecting the cardiovascular and metabolic benefits of the drug.
Survodutide (BI 456906) is a synthetic peptide developed by Boehringer Ingelheim in collaboration with Zealand Pharma, derived structurally from glucagon with a C18 fatty diacid moiety incorporated to enable once-weekly subcutaneous dosing. It was deliberately engineered with a greater potency bias toward the GLP-1 receptor (EC50 approximately 1 nM) than the glucagon receptor (EC50 approximately 8 nM), maintaining the glycemic control and appetite suppression benefits of GLP-1 receptor agonism while adding the energy expenditure and direct hepatic benefits of glucagon receptor agonism.
The rationale for dual GCGR/GLP-1R agonism draws on decades of physiology: GLP-1 receptor activation suppresses appetite, slows gastric emptying, and improves insulin secretion, while glucagon receptor activation stimulates hepatic fat oxidation, increases energy expenditure, and promotes lipid mobilization in adipose tissue. This combination was hypothesized to produce additive weight loss beyond GLP-1 receptor agonism alone, and the liver-specific effects of glucagon receptor activation provide a mechanistic rationale for particular efficacy in MASH.
The drug's development accelerated substantially after Phase 2 results were presented at the ADA 83rd Scientific Sessions in June 2023 and subsequently published in 2024. The obesity Phase 2 results in Lancet Diabetes and Endocrinology and the MASH Phase 2 results in the NEJM established survodutide as one of the leading candidates in the obesity pharmacology pipeline.
Survodutide activates two distinct G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), producing effects through two complementary but partially overlapping pathways.
GLP-1 receptor activation reduces energy intake via hypothalamic appetite suppression, slows gastric emptying (reducing postprandial caloric absorption), stimulates glucose-dependent insulin secretion from pancreatic beta cells, and provides direct cardiovascular protective effects via GLP-1R expressed on cardiomyocytes and endothelial cells. These are the established mechanisms of the approved GLP-1R agonist class (semaglutide, liraglutide, and tirzepatide's GLP-1R component).
Glucagon receptor activation adds complementary mechanisms: stimulation of hepatic fat oxidation and mitochondrial uncoupling (reducing hepatic steatosis), increased adipose tissue lipolysis, elevated energy expenditure via thermogenesis, and hepatic glycogenolysis. The glucagon receptor is highly expressed in the liver, making glucagon receptor agonism a mechanistic driver of the drug's particular hepatic efficacy in MASH. The hepatic effects are largely independent of appetite suppression.
Survodutide was deliberately designed with GLP-1R bias (EC50 approximately 1 nM GLP-1R versus EC50 approximately 8 nM GCGR). This bias leverages GLP-1R-mediated insulin secretion to counterbalance the hyperglycemic potential of unopposed glucagon receptor activation, maintaining euglycemia while capturing the metabolic and hepatic benefits of glucagon receptor signaling.
The combination is hypothesized to produce superior weight loss versus GLP-1R mono-agonism because GLP-1 reduces caloric intake while glucagon increases energy expenditure: two independent levers. Preclinical studies confirmed survodutide reduced body weight in murine models to a greater extent than maximally effective semaglutide, attributed partly to the energy expenditure component.
Le Roux 2024 (n=386, 46 weeks): By planned treatment analysis (modified ITT), mean body weight changes were -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg), -14.9% (4.8 mg), and -2.8% (placebo). The placebo-corrected difference at 4.8 mg was -12.1% (95% CI: -15.0 to -9.2; p less than 0.0001). By actual treatment analysis (completers only), the 4.8 mg group achieved -18.7% versus -2.3% placebo.
83% of completers at 4.8 mg achieved at least 5% body weight loss; 69% achieved at least 10%; 55% achieved at least 15%. Up to 40% of participants at the two highest doses achieved at least 20% weight loss. Body weight was still declining at 46 weeks (no plateau observed), suggesting potential for greater reductions with longer treatment.
Cardiometabolic secondary endpoints at 4.8 mg (placebo-corrected): body weight -15.8 kg (-18.7 to -12.9); waist circumference -12.1 cm (-15.4 to -8.7); systolic BP -6.2 mmHg (-10.3 to -2.1); diastolic BP -2.9 mmHg (-5.4 to -0.5). Safety: 91% AE rate, 75% GI disorders, 25% discontinuation (predominantly during escalation).
The Phase 2 obesity results are among the strongest Phase 2 efficacy data in the incretin drug class. The 18.7% weight loss (completers) at 4.8 mg exceeds the approximately 15% seen with semaglutide 2.4 mg in the STEP 1 Phase 3 trial and is comparable to tirzepatide Phase 2 data that preceded its approval. The continuing weight loss trajectory at 46 weeks indicates potential for greater efficacy with longer treatment. The 25% discontinuation rate is the central concern for Phase 3. Results from SYNCHRONIZE-1 and SYNCHRONIZE-2 (expected H1 2026) will be the definitive test.
Sanyal 2024 (n=293, 48 weeks, biopsy-confirmed MASH F1-F3): The primary endpoint (MASH improvement without fibrosis worsening) was met by 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) versus 14% placebo (p less than 0.001 for the quadratic dose-response model). The 4.8 mg dose produced the highest efficacy.
Secondary endpoints: At least 30% liver fat content reduction occurred in 63% (2.4 mg), 67% (4.8 mg), 57% (6.0 mg), and 14% placebo. At least 1-stage fibrosis improvement occurred in 34%, 36%, 34%, and 22%, respectively. The 6.0 mg group had lower efficacy than 4.8 mg (consistent with GI intolerability at the higher dose reducing on-treatment exposure).
The FDA granted Breakthrough Therapy designation for survodutide in non-cirrhotic MASH with F2 to F3 fibrosis in September 2024. The LIVERAGE Phase 3 MASH program is enrolling; the 52-week primary endpoint plus a 7-year long-term extension will be assessed.
This NEJM publication is the headline data for survodutide. The 62% MASH resolution rate at 4.8 mg substantially exceeds placebo and is competitive with resmetirom (the FDA-approved MASH drug, March 2024), which showed approximately 38% resolution in the MAESTRO-NASH Phase 3 trial. The fibrosis improvement signal is clinically meaningful: fibrosis stage reduction is the endpoint most predictive of long-term liver outcomes. The FDA Breakthrough Therapy designation confirms the agency's view of the data quality and unmet need. LIVERAGE Phase 3 results will be definitive.
Bluher 2024 (n=413 plus comparators, 16 weeks, T2D on metformin): At the highest once-weekly dose (2.7 mg), HbA1c reduction was -1.56% (-17.01 mmol/mol) from a baseline of approximately 8.1%. At 1.8 mg twice weekly, HbA1c reduction was -1.68% (-18.38 mmol/mol). Semaglutide 1 mg produced -1.47% (-16.07 mmol/mol).
Body weight was reduced dose-dependently: the highest dose group (1.8 mg twice weekly, equivalent to 3.6 mg weekly) produced -8.7% weight loss (-10.1 to -7.3%), significantly greater than semaglutide's -5.3% (-6.6 to -4.1%). AEs: 77.8% of survodutide recipients versus 52.5% placebo and 52.0% semaglutide, primarily GI events. Authors noted dose-related GI AEs could be mitigated by slower escalation.
The T2D Phase 2 establishes proof of concept: survodutide achieves glycemic control comparable to semaglutide while producing substantially greater body weight reduction, consistent with the glucagon receptor's additive energy expenditure contribution. The 16-week duration is adequate for HbA1c signal detection but insufficient for long-term glycemic or cardiovascular conclusions. SYNCHRONIZE-2 Phase 3 (obesity plus T2D; enrolled; 76-week; results H1 2026) will provide the definitive T2D dataset.
Phase 2 obesity safety (Le Roux 2024): Treatment-emergent AE rate 91% (survodutide all doses) vs 75% (placebo). GI disorders: 75% vs 42%. Treatment discontinuations due to AEs: 25% (survodutide) vs 4% (placebo). Majority of discontinuations occurred during the 20-week rapid dose-escalation phase. Nausea (66% vs 23%), diarrhea (49% vs 23%), vomiting (41% vs 11%). Serious AEs: 4% vs 7%.
Despite the high AE and discontinuation rates, serious adverse events were less common in survodutide than placebo (4% vs 7%), and no unexpected safety signal was identified. The tolerability profile is consistent with the established GLP-1 receptor agonist class plus glucagon receptor effects.
Phase 3 design modification (Wharton 2025): SYNCHRONIZE trials implement a more gradual dose-escalation schedule, starting at 1 mg and increasing over approximately 32 weeks to maximum maintenance doses (3.6 or 6.0 mg). The hypothesis is that most Phase 2 discontinuations occurred due to overly rapid titration and will be substantially reduced by the slower Phase 3 escalation schedule.
A 25% AE-driven discontinuation rate (vs 4% placebo) is the most important safety signal in the survodutide Phase 2 program. The mechanism is clear (GI effects during rapid dose escalation) and the mitigation strategy (slower escalation) is credible. The more important question is practical: even with slower escalation, GI events will occur in a majority of patients. For a chronic obesity medication requiring indefinite use, tolerability at scale is as important as efficacy in trials. Phase 3 will provide the first answer to whether the real-world tolerability of survodutide is manageable.
SYNCHRONIZE-CVOT design (enrolling as of March 2026): n=4,935 target; three arms (survodutide 6.0 mg, survodutide 3.6 mg, placebo weekly SC); primary endpoint is time to first 5-point major adverse CV event (MACE: death from any cause, non-fatal stroke, non-fatal MI, ischemia-related coronary revascularization, heart failure event). Stratified by heart failure status and T2D status.
This is the first trial specifically designed to determine survodutide's CV outcomes. Context: the SELECT trial (semaglutide 2023) demonstrated 20% reduction in major CV events in people with obesity without T2D, establishing a class effect for GLP-1R agonism. The SYNCHRONIZE-CVOT is designed to determine whether glucagon receptor agonism attenuates or complements this CV benefit. The glucagon receptor's known effects on heart rate elevation require formal cardiovascular safety assessment.
Cardiovascular outcomes data for survodutide will not be available for several years after the obesity and MASH Phase 3 results. The event-driven design means SYNCHRONIZE-CVOT could run until 2028 or beyond depending on event accrual rates. If survodutide is approved for obesity in 2027, prescribers will face an uncertain CV safety profile until CVOT completion. This is the standard situation for newly approved obesity drugs; however, the glucagon component adds a theoretical question about heart rate effects that the GLP-1-only class does not carry.
Phase 2 trials tested 0.6-4.8mg for obesity.
Survodutide is an investigational pharmaceutical drug available only through clinical trials and cannot be obtained by prescription or compounding pharmacy. The Phase 3 dose escalation is more gradual than Phase 2: starting at 1 mg and escalating over approximately 32 weeks to the maximum maintenance dose (3.6 or 6.0 mg). This design change specifically targets the 25% GI-driven discontinuation rate observed in Phase 2. The optimal Phase 2 dose for both obesity and MASH was 4.8 mg; Phase 3 maximum doses are 3.6 and 6.0 mg to allow evaluation of both doses in the broader population.
Within this series, survodutide (Tier 2, Phase 2 positive, Phase 3 enrolled) sits between semaglutide and tirzepatide (both Tier 1, FDA-approved) and retatrutide (Tier 2, Phase 2, Eli Lilly's GLP-1/GIP/glucagon triple agonist). The mechanistic distinction is important: tirzepatide (Zepbound) activates GLP-1 plus GIP; survodutide activates GLP-1 plus glucagon; retatrutide activates all three. The glucagon component distinguishes survodutide from tirzepatide with particular relevance to MASH, where hepatic glucagon receptor agonism directly stimulates fat oxidation. In terms of Phase 2 weight loss magnitude, survodutide's data is competitive with tirzepatide's Phase 2 data (SURPASS series) that preceded approval. The MASH indication is where survodutide has the clearest mechanistic and clinical differentiation from all existing approved drugs except resmetirom (a thyroid receptor beta agonist, approved March 2024 for MASH).
The Phase 2 safety profile is characterized by high rates of gastrointestinal adverse events and a clinically significant but dose-escalation-related treatment discontinuation rate.
Phase 2 obesity trial (Le Roux et al. 2024, n=386, 46 weeks): treatment-emergent AEs occurred in 91% of survodutide recipients (all doses pooled) and 75% of placebo recipients. GI disorders were the primary adverse events (75% vs 42%). Treatment discontinuation due to AEs occurred in 25% of survodutide recipients versus 4% placebo, with most discontinuations occurring during the 20-week dose-escalation phase. Nausea (66% vs 23%), diarrhea (49% vs 23%), and vomiting (41% vs 11%) were the most common events. Serious adverse events were less frequent in survodutide (4%) than placebo (7%).
Phase 2 MASH trial (Sanyal et al. 2024, n=293, 48 weeks): similar AE profile; consistent with the obesity trial data.
Blood pressure favorable effects: at 4.8 mg, placebo-corrected reductions of -6.2 mmHg systolic and -2.9 mmHg diastolic at 46 weeks, indicating metabolic benefit beyond weight loss.
No pancreatitis signal was identified in Phase 2. The class-effect concern for thyroid C-cell tumors (seen with GLP-1R agonists in rodents) has not been observed in available human data. Heart rate increases (a class effect of GLP-1R agonism, and also a glucagon receptor effect) were observed, consistent with mechanism.
Phase 3 tolerability approach: SYNCHRONIZE trials use a significantly slower dose-escalation schedule than Phase 2 (starting at 1 mg, escalating over approximately 32 weeks to maximum maintenance doses of 3.6 or 6.0 mg) specifically to reduce GI-driven discontinuations. Whether this achieves a meaningful reduction in the discontinuation rate will be determined by Phase 3 results.
Survodutide is the most clinically advanced compound in this series outside the FDA-approved drugs, and its Phase 2 evidence base is genuinely strong. Two major Phase 2 RCTs published in 2024 in the NEJM and Lancet demonstrate compelling results: up to 18.7% weight loss (completers) at 46 weeks in obesity and 62% MASH resolution at 48 weeks, both substantially exceeding placebo and competitive with the best available comparators. The FDA Breakthrough Therapy designation for MASH reflects the clinical unmet need and data quality.
The central uncertainty is Phase 3 replication. The SYNCHRONIZE obesity trials (enrolled, results H1 2026) and LIVERAGE MASH trials will determine whether Phase 2 holds at scale. If successful, FDA approval could follow in 2027. The 25% GI-driven discontinuation rate in Phase 2 is the primary commercial risk, though the Phase 3 design specifically addresses this with slower escalation.
Cardiovascular outcome data from SYNCHRONIZE-CVOT (n=4,935) will not be available for years after potential approval. This leaves the CV risk-benefit profile partially incomplete at the time of any initial approval, which is the standard situation for newly approved obesity drugs.
Survodutide cannot be obtained outside a formal clinical trial at present. For clinicians and patients following the obesity and MASH pharmacology pipeline, this is one of the most closely watched 2026 readouts.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use